These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16735150)

  • 1. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
    Rose WE; Rybak MJ; Tsuji BT; Kaatz GW; Sakoulas G
    J Antimicrob Chemother; 2007 Jun; 59(6):1190-3. PubMed ID: 17434881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.
    Schentag JJ
    J Chemother; 1999 Dec; 11(6):426-39. PubMed ID: 10678784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.
    Lee SJ; Awji EG; Park NH; Park SC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
    Parra-Ruiz J; Hernández-Quero J
    Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus.
    Tsuji BT; Rybak MJ; Lau KL; Sakoulas G
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1089-91. PubMed ID: 17158941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles.
    Nicolau DP
    Infection; 2001 Dec; 29 Suppl 2():11-5. PubMed ID: 11785851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
    Vallé M; Schneider M; Galland D; Giboin H; Woehrlé F
    J Vet Pharmacol Ther; 2012 Dec; 35(6):519-28. PubMed ID: 22126438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
    Nicolau DP
    J Infect Chemother; 2003 Dec; 9(4):292-6. PubMed ID: 14691648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
    Xiao XM; Xiao YH
    Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.
    Andes D; Anon J; Jacobs MR; Craig WA
    Clin Lab Med; 2004 Jun; 24(2):477-502. PubMed ID: 15177850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW; Ward KW
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
    Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
    Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.
    Craig WA
    Respir Med; 2001 Jun; 95 Suppl A():S12-9; discussion S26-7. PubMed ID: 11419669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
    Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.